Clinical Trials Logo

Myeloproliferative Neoplasm clinical trials

View clinical trials related to Myeloproliferative Neoplasm.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04994158 Enrolling by invitation - Clinical trials for Myeloproliferative Neoplasm

MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis

MASCOT-R
Start date: September 1, 2019
Phase:
Study type: Observational [Patient Registry]

A registry of UK patients diagnosed to have splanchnic vein thrombosis and myeloproliferative neoplasm, including isolated mutation of JAK2V617f. The purpose of the registry is to understand outcomes, treatment variations and data to inform and enable future clinical trial design and facilitate regulatory approval decision-making.

NCT ID: NCT04024761 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Start date: August 31, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT) or HLA matched stem cells. This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years of age or older) with AML, MDS, JMML who relapse after stem cell transplantation using HLA-matched related donor or related donor haploidentical stem cells.